Interview: Vivoryon Raises €43m After Alzheimer's Revival
German Biotech Can Fund PQ912 Phase IIb Trials
New life has been breathed into Alzheimer's research following the reversal of fortunes for Biogen's aducanumab and Vivoryon is benefiting from the upturn in sentiment for the field.
